203 related articles for article (PubMed ID: 23915561)
1. Galactosialidosis: review and analysis of CTSA gene mutations.
Caciotti A; Catarzi S; Tonin R; Lugli L; Perez CR; Michelakakis H; Mavridou I; Donati MA; Guerrini R; d'Azzo A; Morrone A
Orphanet J Rare Dis; 2013 Aug; 8():114. PubMed ID: 23915561
[TBL] [Abstract][Full Text] [Related]
2. [Galactosialidosis: a new "de novo" mutation in CTSA gene in a patient with late infantile galactosialidosis].
García Hernández L; Sierra Sirvent J; Gort Mas L; Coll Roseli MJ
Arch Argent Pediatr; 2018 Feb; 116(1):e88-e92. PubMed ID: 29333829
[TBL] [Abstract][Full Text] [Related]
3. New mutations in the PPBG gene lead to loss of PPCA protein which affects the level of the beta-galactosidase/neuraminidase complex and the EBP-receptor.
Malvagia S; Morrone A; Caciotti A; Bardelli T; d'Azzo A; Ancora G; Zammarchi E; Donati MA
Mol Genet Metab; 2004 May; 82(1):48-55. PubMed ID: 15110321
[TBL] [Abstract][Full Text] [Related]
4. A Turkish case of galactosialidosis with a new homozygous mutation in CTSA gene.
Kartal A; Aydın K
Metab Brain Dis; 2017 Aug; 32(4):973-975. PubMed ID: 28555253
[TBL] [Abstract][Full Text] [Related]
5. Lysosomal sialidase NEU1, its intracellular properties, deficiency, and use as a therapeutic agent.
Itoh K; Tsukimoto J
Glycoconj J; 2023 Dec; 40(6):611-619. PubMed ID: 38147151
[TBL] [Abstract][Full Text] [Related]
6. New CTSA mutation in early infantile galactosialidosis.
Aldámiz-Echevarría L; Couce ML; Villate O; Fernández-Marmiesse A; Piñán MÁ
Pediatr Int; 2018 Aug; 60(8):761-762. PubMed ID: 29987886
[No Abstract] [Full Text] [Related]
7. New mutations in two Dutch patients with early infantile galactosialidosis.
Groener J; Maaswinkel-Mooy P; Smit V; van der Hoeven M; Bakker J; Campos Y; d'Azzo A
Mol Genet Metab; 2003 Mar; 78(3):222-8. PubMed ID: 12649068
[TBL] [Abstract][Full Text] [Related]
8. A case of galactosialidosis with novel mutations of the protective protein/cathepsin a gene: diagnosis prompted by trophoblast vacuolization on placental examination.
Kostadinov S; Shah BA; Alroy J; Phornphutkul C
Pediatr Dev Pathol; 2014; 17(6):474-7. PubMed ID: 25075748
[TBL] [Abstract][Full Text] [Related]
9. Galactosialidosis: historic aspects and overview of investigated and emerging treatment options.
Annunziata I; d'Azzo A
Expert Opin Orphan Drugs; 2017; 5(2):131-141. PubMed ID: 28603679
[TBL] [Abstract][Full Text] [Related]
10. Molecular and biochemical analysis of protective protein/cathepsin A mutations: correlation with clinical severity in galactosialidosis.
Zhou XY; van der Spoel A; Rottier R; Hale G; Willemsen R; Berry GT; Strisciuglio P; Morrone A; Zammarchi E; Andria G; d'Azzo A
Hum Mol Genet; 1996 Dec; 5(12):1977-87. PubMed ID: 8968752
[TBL] [Abstract][Full Text] [Related]
11. Role of beta-galactosidase and elastin binding protein in lysosomal and nonlysosomal complexes of patients with GM1-gangliosidosis.
Caciotti A; Donati MA; Boneh A; d'Azzo A; Federico A; Parini R; Antuzzi D; Bardelli T; Nosi D; Kimonis V; Zammarchi E; Morrone A
Hum Mutat; 2005 Mar; 25(3):285-92. PubMed ID: 15714521
[TBL] [Abstract][Full Text] [Related]
12. A case of galactosialidosis with a homozygous Q49R point mutation.
Matsumoto N; Gondo K; Kukita J; Higaki K; Paragison RC; Nanba E
Brain Dev; 2008 Oct; 30(9):595-8. PubMed ID: 18396002
[TBL] [Abstract][Full Text] [Related]
13. A new heterozygous compound mutation in the
Nakajima H; Ueno M; Adachi K; Nanba E; Narita A; Tsukimoto J; Itoh K; Kawakami A
Hum Genome Var; 2019; 6():22. PubMed ID: 31044084
[TBL] [Abstract][Full Text] [Related]
14. Chemical chaperone treatment for galactosialidosis: Effect of NOEV on β-galactosidase activities in fibroblasts.
Hossain MA; Higaki K; Shinpo M; Nanba E; Suzuki Y; Ozono K; Sakai N
Brain Dev; 2016 Feb; 38(2):175-80. PubMed ID: 26259553
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathology of galactosialidosis in a patient affected with two new frameshift mutations in the cathepsin A/protective protein gene.
Richard C; Tranchemontagne J; Elsliger MA; Mitchell GA; Potier M; Pshezhetsky AV
Hum Mutat; 1998; 11(6):461-9. PubMed ID: 9603439
[TBL] [Abstract][Full Text] [Related]
16. The atomic model of the human protective protein/cathepsin A suggests a structural basis for galactosialidosis.
Rudenko G; Bonten E; Hol WG; d'Azzo A
Proc Natl Acad Sci U S A; 1998 Jan; 95(2):621-5. PubMed ID: 9435242
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of whole-exome sequencing in rare diseases: Galactosialidosis.
Prada CE; Gonzaga-Jauregui C; Tannenbaum R; Penney S; Lupski JR; Hopkin RJ; Sutton VR
Eur J Med Genet; 2014 Jul; 57(7):339-344. PubMed ID: 24769197
[TBL] [Abstract][Full Text] [Related]
18. Stable expression of protective protein/cathepsin A-green fluorescent protein fusion genes in a fibroblastic cell line from a galactosialidosis patient. Model system for revealing the intracellular transport of normal and mutated lysosomal enzymes.
Naganawa Y; Itoh K; Shimmoto M; Kamei S; Takiguchi K; Doi H; Sakuraba H
Biochem J; 1999 Jun; 340 ( Pt 2)(Pt 2):467-74. PubMed ID: 10333491
[TBL] [Abstract][Full Text] [Related]
19. Lysosomal multienzymatic complex-related diseases: a genetic study among Portuguese patients.
Coutinho MF; Lacerda L; Macedo-Ribeiro S; Baptista E; Ribeiro H; Prata MJ; Alves S
Clin Genet; 2012 Apr; 81(4):379-93. PubMed ID: 21214877
[TBL] [Abstract][Full Text] [Related]
20. Elastogenesis in cultured dermal fibroblasts from patients with lysosomal beta-galactosidase, protective protein/cathepsin A and neuraminidase-1 deficiencies.
Tatano Y; Takeuchi N; Kuwahara J; Sakuraba H; Takahashi T; Takada G; Itoh K
J Med Invest; 2006 Feb; 53(1-2):103-12. PubMed ID: 16538002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
